tiprankstipranks
Motus GI Holdings price target lowered to $6 from $10 at Piper Sandler
The Fly

Motus GI Holdings price target lowered to $6 from $10 at Piper Sandler

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Motus GI Holdings to $6 from $10 but keeps an Overweight rating on the shares. The company’s Q3 results were just shy of expectations on the top line, but its clinical pipeline is on track for headway in both Pure Vu Gastro and the outpatient reimbursement trial, both of which should be tailwinds to the business, the analyst tells investors in a research note. O’Brien adds that he remains optimistic about the potential of Motus GI’s technology and continues to recommend the name to risk-tolerant investors.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on MOTS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles